Jump to content

James X. Zhang

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 03:34, 28 June 2020 (top: HTTP → HTTPS for ABC News, replaced: http://abcnews.go.com/ → https://abcnews.go.com/). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

James X. Zhang is an American health economist and health services researcher at the University of Chicago known for his innovative approaches in exploring complex data to measure a range of factors influencing healthcare delivery and outcomes.

Zhang initially worked with Nicholas Christakis, and the products included a novel methodology for identifying married couples in the Medicare claims to study mortality, morbidity, and health care use among the married elderly,[1] and a novel claims-based dataset exploiting substantial cross-set linkages to study end-of-life care.[2]

Zhang's research addressed the significance of comorbidity in clinical setting, and was among the most frequently cited papers in the field.[3] His contribution also included that to some other influential study[4] in the field of Medicare Part D program, and generic drug use.[5][6][7] His more recent contributions with David O. Meltzer includes a novel method identifying patient with cost-related medication non-adherence using a big-data approach.[8] His most recent contribution aims to advance the understanding of gender role in healthcare behaviors and outcomes.[9][10]

References

  1. ^ Iwashyna TJ, Zhang JX, Lauderdale DS, Christakis NA. A methodology for identifying married couples in Medicare data: mortality, morbidity, and health care use among the married elderly. Demography 1998; 35 (4): 413-419. JSTOR 3004010
  2. ^ Christakis NA, Iwashyna TJ, Zhang JX. Care after the onset of serious illness: a novel claims-based dataset exploiting substantial cross-set linkages to study end-of-life care. J Palliat Med. 2002 Aug;5(4):515-29.
  3. ^ Zhang, JX, Iwashyna TJ, Christakis NA. The Performance of Different Lookback Periods and Sources of Information for Charlson Comorbidity Adjustment in Medicare Claims. Medical Care 1999; 37(11):1128-1139 JSTOR 3767066
  4. ^ http://www-news.uchicago.edu/releases/08/080108.medicare.shtml
  5. ^ https://abcnews.go.com/Health/top-selling-drugs-coming-off-patent-paving-cheaper/story?id=13048629
  6. ^ Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine 2008; 148 (3): 169-177.
  7. ^ Zhang JX, Yin W, Shawn S, Alexander GC. The impact of the Medicare Part D prescription benefit on generic drugs use. Journal of General Internal Medicine 2008;23(10):1673-1678.
  8. ^ Zhang JX, Meltzer DO. Identifying patients with cost-related medication non-adherence: a big-data approach. J Med Econ. 2016 Apr 15:1-6.
  9. ^ Gender and Cost-related Medication Non-adherence. Cancer Therapy Advisor. http://www.cancertherapyadvisor.com/general-oncology/gender-cost-related-medication-non-adherence/article/628116/
  10. ^ Zhang JX, Crowe JM, Meltzer DO. The differential rates in cost-related non-adherence to medical care by gender in the U.S. adult population. J Med Econ. 2017 May 3:1-17. doi: 10.1080/13696998.2017.1326383. [Epub ahead of print] PubMed PMID 28466689